Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) --
-- Company prioritizing THE-349, a potentially best-in-class fourth-generation EGFR inhibitor for EGFR mutant non-small cell lung cancer; IND on track for submission in Q4 2023 --
-- Theseus announces new program targeting KIT for patients with early-line GIST; development candidate nomination expected in the H1 2024 --
-- Development candidate nomination from BCR-ABL program also expected in H1 2024 --
-- $234 million in cash, cash equivalents, and marketable securities as of June 30, 2023; runway extended into 2026 --
https://finance.yahoo.com/news/theseus-pharmaceuticals-discontinue-enrollment-phase-200500221.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.